.jpg)
.jpg)
.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Vertex has backed out of its in vivo gene editing collaboration with Verve Thera...
“While we remain confident in our zerlasiran program for high Lp(a), we will onl...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Human medicines European public assessment report (EPAR): Advagraf, tacrolimus, ...
Even as President Donald Trump wages a very public fight against diversity, equi...
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, D...
Human medicines European public assessment report (EPAR): Remicade, infliximab, ...
Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib,...
Human medicines European public assessment report (EPAR): Welireg, belzutifan, S...
UK drugmaker says Emma Walmsley is underpaid compared with global competitors
Guidance on the details of the classification of variations requiring assessment...
Infographic - Orphan Medicines in the EU
Why one health care investor buys “zombie” biotechs to shut them down.
Human medicines European public assessment report (EPAR): Soliris, eculizumab, D...
The federal government’s work on long Covid has been fitful and disappointing. N...
A progressive approach to drug approval would balance the reality of drug safety...
Universities accept less than their actual overhead costs from private sources b...
Biotech venture capital is on the precipice of a generational shift. At least, t...
Human medicines European public assessment report (EPAR): Spinraza, nusinersen, ...
Human medicines European public assessment report (EPAR): Xalkori, crizotinib, D...
Addendum to the Guideline on clinical development of vaccines to address clinica...
Clinical Trial Information System (CTIS) evaluation timelines
Clinical evaluation of new vaccines - Scientific guideline
Human medicines European public assessment report (EPAR): Voydeya, Danicopan, Da...